Please login to the form below

Not currently logged in
Email:
Password:

Biomunex appoints scientific and strategic advisors

Dr Sebastian Amigorena and Dr Dragan Grabulovski

Biomunex Dr Sebastian AmigorenaParis, France-based immuno-oncology specialist Biomunex Pharmaceuticals has appointed Dr Sebastian Amigorena and Dr Dragan Grabulovski as key scientific advisor and key strategic advisor, respectively.

Dr Amigorena (pictured right) is currently a research director at Le Centre National de la Recherché Scientifique (CNRS) and is director of the Inserm Immunity and Cancer Unit at the Institut Curie in Paris.

In his role as scientific advisory, he will help the company to leverage its 'Plug-and-Play' antibody platform for the development of Biomunex's immunotherapeutics pipeline.

Biomunex Dr Dragan GrabulovskiMeanwhile, Dr Grabulovski (pictured left) is a pharmaceutical biotechnology advisor at Grabulovski Consulting Services, having previously served as chief scientific officer of Covagen, which he co-founded.

Prior to Covagen's sales to Johnson & Johnson in 2014, Dr Grabulovski was responsible for the Swiss biotech's research and development strategy, including its Fynomer technology.

Dr Pierre-Emmanuel Gerard, chief executive officer at Biomunex, said: “We are very pleased to welcome Dr Amigorena and Dr Grabulovski as key advisors.

“As international key opinion leaders they will play an instrumental role as we advance our first oncology programmes into pre-clinical and clinical development."

22nd December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics